Table 1 Characteristics of patients included in the study
|  | IPF (n = 49) |
|---|---|
Age, years | 73.0 ± 7.7 |
Sex, female, n (%) | 5 (10.2%) |
Body mass index, kg/m.2 | 22.3 ± 3.11 |
Smoking history | |
 Current or ex-smoker, n (%) | 41 (83.7%) |
 Pack-years | 30 [10–46] |
Histological diagnosis, n (%) | 15 (30.6%) |
Severity | |
 GAP index | 3 [3, 4] |
 GAP stage (I/II/III), n (%) | 30 (61%)/19 (39%)/0 (0%) |
Pulmonary function | |
 FVC, % predicted | 80.4 ± 15.5 |
 FEV1/FVC, % | 81.9 ± 8.81 |
 DLCO, % predicted | 67.4 ± 19.1 |
 PaO2, mmHg | 87.9 [79.1–98.1] |
Physical assessment | |
 Handgrip strength, kg | |
  Male | 7.0 ± 0.9 |
  Female | 5.3 ± 0.5 |
 Usual gait speed, m/s | 1.10 ± 0.26 |
 6MWT | |
  Distance, m | 416 ± 88 |
  Lowest SpO2, % | 89 [85–92] |
 ASMI, kg/m2 | |
  Male | 7.0 ± 0.9 |
  Female | 5.3 ± 0.5 |
SARC-F | 2 [1–3.5] |
Patient reported outcome | |
 mMRC | 1 [0–2] |
 CAT | 13 [6.5–21] |
 K-BILD | |
  Psychological | 56.9 [48.4–64.3] |
  Breathlessness and activities | 50.2 [41.9–58.5] |
  Chest symptoms | 73.4 [63.7–79.3] |
  Total | 59.5 [54.2–62.7] |
Blood examination | |
 Creatinine (mg/dL) | 0.84 [0.75–0.99] |
 Cystatin C (mg/L) | 1.00 [0.89–1.21] |
 Cr/CysC ratio | 0.86 [0.76–0.94] |
Comorbidity | |
 Hypertension, n (%) | 28 (57.1%) |
 Dyslipidemia, n (%) | 18 (36.7%) |
 Diabetes mellitus, n (%) | 13 (26.5%) |
 Coronary artery disease, n (%) | 5 (10.2%) |
 Chronic kidney disease, n (%) | 2 (4.1%) |
 Sarcopenia, n (%) | 18 (36.7%) |